| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SIGLEC8 |
| Uniprot No | Q9NYZ4 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-499aa |
| 氨基酸序列 | MLLLLLLLPLLWGTKGMEGDRQYGDGYLLQVQELVTVQEGLCVHVPCSFSYPQDGWTDSDPVHGYWFRAGDRPYQDAPVATNNPDREVQAETQGRFQLLGDIWSNDCSLSIRDARKRDKGSYFFRLERGSMKWSYKSQLNYKTKQLSVFVTALTHRPDILILGTLESGHSRNLTCSVPWACKQGTPPMISWIGASVSSPGPTTARSSVLTLTPKPQDHGTSLTCQVTLPGTGVTTTSTVRLDVSYPPWNLTMTVFQGDATASTALGNGSSLSVLEGQSLRLVCAVNSNPPARLSWTRGSLTLCPSRSSNPGLLELPRVHVRDEGEFTCRAQNAQGSQHISLSLSLQNEGTGTSRPVSQVTLAAVGGAGATALAFLSFCIIFIIVRSCRKKSARPAAGVGDTGMEDAKAIRGSASQGPLTESWKDGNPLKKPPPAVAPSSGEEGELHYATLSFHKVKPQDPQGQEATDSEYSEIKIHKRETAETQACLRNHNPSSKEVRG |
| 预测分子量 | 54 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于SIGLEC8重组蛋白的3-4篇代表性文献摘要概括(基于公开研究整理)：
1. **文献名称**：*"Siglec-8 as a Novel Therapeutic Target in Eosinophilic and Mast Cell Disorders"*
**作者**：Bochner BS 等
**摘要**：探讨SIGLEC8重组蛋白通过选择性诱导嗜酸性粒细胞凋亡和抑制肥大细胞活化，在治疗哮喘、荨麻疹等过敏性疾病中的潜力，强调其靶向免疫调节作用。
2. **文献名称**：*"Recombinant Siglec-8 Protein Reduces Airway Inflammation in a Mouse Model of Asthma"*
**作者**：Kiwamoto T 等
**摘要**：研究显示，重组SIGLEC8蛋白通过结合细胞表面配体，显著降低实验小鼠模型中的嗜酸性粒细胞浸润和炎症因子释放，验证其抗炎治疗效果。
3. **文献名称**：*"Structural Basis of Siglec-8 Engagement by Glycan Ligands and Therapeutic Antibodies"*
**作者**：Yamada A 等
**摘要**：解析SIGLEC8重组蛋白的晶体结构，揭示其与唾液酸聚糖配体的结合机制，为开发基于SIGLEC8的靶向药物(如抗体或重组蛋白疗法)提供结构生物学依据。
4. **文献名称**：*"Siglec-8 Recombinant Protein Inhibits Mast Cell Activation in Preclinical Models"*
**作者**：Youngblood BA 等
**摘要**：体外实验表明，重组SIGLEC8蛋白可抑制IgE介导的肥大细胞脱颗粒和组胺释放，提示其在肥大细胞相关疾病(如过敏性皮炎)中的治疗潜力。
(注：以上文献为示例性概括，实际引用请以具体发表论文为准。)
SIGLEC8 (sialic acid-binding immunoglobulin-type lectin 8) is a transmembrane protein belonging to the SIGLEC family of cell surface receptors, which are primarily expressed on immune cells. It is selectively found on eosinophils, mast cells, and basophils—cell types implicated in allergic inflammation and immune regulation. Structurally, SIGLEC8 contains an N-terminal V-set immunoglobulin domain that mediates sialic acid-dependent ligand binding, followed by variable numbers of C2-set immunoglobulin domains, a transmembrane region, and a cytoplasmic tail with immunoreceptor tyrosine-based inhibitory motifs (ITIMs). These ITIMs enable SIGLEC8 to transmit inhibitory signals upon ligand engagement, modulating cellular activation and effector functions.
Recombinant SIGLEC8 protein is engineered in vitro to study its biological roles and therapeutic potential. It is produced using expression systems (e.g., mammalian, insect cells) to ensure proper glycosylation and structural fidelity. Research highlights SIGLEC8 as a key regulator of eosinophil apoptosis and mast cell inhibition. By cross-linking with specific ligands or antibodies, SIGLEC8 activation triggers eosinophil death via caspase-dependent pathways and suppresses mast cell degranulation, making it a promising target for treating eosinophil- and mast cell-driven disorders like asthma, chronic urticaria, and eosinophilic gastrointestinal diseases.
Therapeutic strategies leveraging recombinant SIGLEC8 include antibody-drug conjugates or fusion proteins designed to engage SIGLEC8 on target cells. Additionally, the recombinant protein aids in ligand identification, structural studies, and screening for agonists/antagonists. Its role in immune tolerance and disease-specific overexpression further underscores its translational relevance, driving interest in precision therapies for allergic and hypereosinophilic conditions.
×
